Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced that it has advanced ALX-0061, a new Nanobody®-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases.
Pancreatitis is often a fatal condition, in which the pancreas digests itself and surrounding tissue. Scientists have previously found that alcohol can trigger the condition by combining with fatty acids in the pancreas, which leads to an excessive release of stored calcium ions. Once calcium ions enter cell fluid in the pancreas it activates digestive enzymes and damages the cells.
Varian Medical Systems, Inc., (NYSE: VAR) announced it has acquired the assets of Houston-based IKOEmed and IKOEtech, privately-owned suppliers of software used in the planning of radiotherapy and radiosurgery treatments.
Baxter International Inc. (NYSE:BAX) announced today a definitive agreement with Edwards Lifesciences Corporation (NYSE:EW) under which Baxter will acquire certain assets related to Edwards' hemofiltration product line, also known as Continuous Renal Replacement Therapy (CRRT). The transaction is expected to close in the third quarter of 2009, pending regulatory approvals.
Centocor Ortho Biotech Inc. announced today that a federal jury has returned a verdict of $1.67 billion against Abbott Laboratories in a patent infringement suit. "We are pleased that the jury has ruled in our favor in the patent litigation case against Abbott," said Kim Taylor, President, Centocor Ortho Biotech Inc.
"Epidemiology is always important and topical, though sometimes unsung," says Professor Johan Giesecke, Chief Scientist at ECDC, the European Centre for Disease Prevention and Control, "but the third applied Infectious Disease Epidemiology Conference in Stockholm in October this year will be an oppor
A team of researchers has demonstrated that a new method for detecting and quantifying protein biomarkers in body fluids may ultimately make it possible to screen multiple biomarkers in hundreds of patient samples, thus ensuring that only the strongest biomarker candidates will advance down the development pipeline.
Interest and concern about possible health threats posed by endocrine-disrupting chemicals (EDCs) is on the rise, yet there is currently no comprehensive coordinated approach to regulating EDCs in the United States.
When it comes to characteristics associated with muscle dysmorphia, there is no difference between bodybuilders who use steroids and those who do not, a University of Arkansas researcher found. Muscle dysmorphia is a disorder characterized by an individual's excessive preoccupation with muscularity and body fat percentage, usually in bodybuilding.
The Medicines and Healthcare products Regulatory Agency (MHRA) and the Appointments Commission are pleased to announce two new appointments and two reappointments of non-executive directors to the Agency Board. Sir John Lilleyman is a newly appointed member to the Agency Board.
